Curative effect and safety of Xuezhikang Capsule in patients with unstable angina pectoris complicating ;elevated liver enzymes

CUI Fang; WEI Qing-min; LIU Cui-hua; ZHANG Meng

doi:10.3969/j.1674-4055.2014.02.26

Abstract：Objective To investigate the curative effect and safety of Xuezhikang Capsule in patients with unstable angina pectoris (UAP) complicating elevated liver enzymes. Methods The patients (n=96) with UAP and liver enzymes elevated by 3 times after taking atorvastatin were randomly divided into group A (stopping taking atorvastatin), group B (taking half-dose atorvastatin) and group C (taking Xuezhikang Capsule only, each n=32). The total therapeutic course was 4 w. The levels of total cholesterol (TC), high-density lipoprotein-cholesterol (HDL-C), low-density lipoprotein-cholesterol (LDL-C), triglyceride (TG), high-sensitivity C-reactive protein (hs-CRP) and alanine aminotransferase (ALT) were detected before and after treatment. The incidence of major adverse cardiac events (MACE) was followed up including cardiac death, fatal myocardial infarction (MI), non-fatal MI and sudden death. Results After treatment for 4 w, ALT level decreased significantly in 3 groups (P<0.05), which was more significant in group A and group C (P<0.05), but there was no statistical difference between group A and group C (P>0.05). After treatment for 4 w, the levels of TC, LDL-C, TG and hs-CRP decreased in group B and group C (P<0.05). The level of HDL-C increased in group C after treatment (P<0.05). The decreases of levels of TC, LDL-C, TG and hs-CRP were not significant (P>0.05) in group A after treatment. Compared with group A after treatment, the levels of TG and hs-CRP decreased significantly in group C (P<0.05). The incidence of MACE was 12.5%in group A, 9.4%in group B and 3.1%in group C (P<0.05). Conclusion In UAP patients with elevated liver enzymes induced by atorvastatin, Xuezhikang Capsule is safe and effective for them. Because of the study has less cases, further trials are needed to proof the results.